People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2020 |
| Silverback Therapeutics, Inc. | — | Biotechnology | Series C | $139.3M | $3.2B | 2020 |
| Guide Therapeutics, Inc. | — | Pharma | Series A | $13.9M | $173.6M | 2020 |
Robert Hershberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Hershberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Peter Thompson | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Andrew Perlman | 1 | 15 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Carl Weissman | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Laura Shawver | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| Peter A. Thompson | 1 | 5 |
| William Rastetter | 1 | 4 |
| John Mendlein | 1 | 4 |
| AMIR S. NASHAT | 1 | 3 |
| Vickie L. Capps | 1 | 3 |
| ROBERT S. EPSTEIN | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.